David E. Gilham

Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.

Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases.

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.

Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.

Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.

Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK.

Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.

Eotaxin-2 and colorectal cancer: a potential target for immune therapy.

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.

The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy.

Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors.

Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis.

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

Development of adoptive cell therapy for cancer: a clinical perspective.

Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent.

Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.

Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?

Chimeric antigen receptors for T-cell based therapy.

Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.

Targeting T cells to tumor: exploiting the chimeric antibody receptor.

Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol.

CAR T cells: driving the road from the laboratory to the clinic.

Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.